NON-SELECTIVE INHIBITION OF BASAL GLUCAGON RELEASE BY [ d -CYS14]-ANALOGUES OF SOMATOSTATIN IN THE RAT
F. Märki, B. Kamber, H Rink, Peter Sieber
Abstract
F. Märki, B. Kamber, H Rink, Peter Sieber
Abstract
The effects of two [D-Cys14]-analogues of somatostatin on basal plasma levels of glucagon, insulin and glucose were determined in unanaesthetized rats to re-examine a glucagon-selective action of these peptides which has been claimed by others. Somatostatin, [D-Cys14]-somatostatin and [D-Trp8, D-Cys14]-somatostatin caused a short-lasting, dose-dependent decrease of plasma glucagon and insulin but they had no significant influence on plasma glucose. Glucagon and insulin reached the nadir 2 min after intravenous injection of the peptides (dose range 1--10 micrograms/kg) or 5 min after subcutaneous administration (30 and 300 micrograms/kg). At the nadir, insulin was decreased to a greater extent than glucagon and the effecer the nadir and at high doses, the time-course of some effects of the analogues on either glucagon or insulin differed from that of somatostatin. Thus, these [D-Cys14]-analogues may show partial kinetic dissociation of effects on glucagon and insulin but they are not truly selective inhibitors of glucagon release.
OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The effects of two [D-Cys14]-analogues of somatostatin on basal plasma levels of glucagon, insulin and glucose were determined in unanaesthetized rats to re-examine a glucagon-selective action of these peptides which has been claimed by others. Somatostatin, [D-Cys14]-somatostatin and [D-Trp8, D-Cys14]-somatostatin caused a short-lasting, dose-dependent decrease of plasma glucagon and insulin but they had no significant influence on plasma glucose. Glucagon and insulin reached the nadir 2 min after intravenous injection of the peptides (dose range 1--10 micrograms/kg) or 5 min after subcutaneous administration (30 and 300 micrograms/kg). At the nadir, insulin was decreased to a greater extent than glucagon and the effecer the nadir and at high doses, the time-course of some effects of the analogues on either glucagon or insulin differed from that of somatostatin. Thus, these [D-Cys14]-analogues may show partial kinetic dissociation of effects on glucagon and insulin but they are not truly selective inhibitors of glucagon release.
Key concepts: Somatostatin, Internal medicine, Endocrinology, Glucagon, Basal (medicine), Chemistry, Medicine, Hormone